Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of empasiprubart IV in adults with CIDP
2025-520805-10-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Empasiprubart IV with Placebo IV (2 arms). Primary endpoint: Reduction of at least 1 point in adjusted INCAT score at week 24. Planned start Mar 2026; status: authorised.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2025-520805-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520805-10-00.